Alphatec vs. Inspire Medical Systems: Which Healthcare Stock Is a Better Buy in 2026?

Alphatec posted FY2025 revenue of $764.2 million, up 25.0%, but still generated a net loss of $143.4 million and carries a high 17.2x debt-to-equity ratio. Inspire Medical Systems delivered stronger fundamentals with FY2025 revenue of about $912.0 million, 13.6% growth, $145.4 million in net income, and a 15.9% net margin, but faces reimbursement and DOJ-related uncertainty. The article favors Alphatec for 2026 on a relative risk basis, though the overall piece is largely comparative analysis rather than fresh market-moving news.

Analysis

The cleaner long here is ATEC, but not because it is “cheaper” — because the market is likely underpricing the second-order operating leverage from procedure mix and installed-base expansion. In spine, once surgeon workflow adoption crosses a threshold, the business gets disproportionate benefit from repeat utilization, service attach, and incremental capital placement; that tends to show up over 6-12 months, not quarters, and can make revenue growth look much more durable than headline margins imply. The catch is that leverage cuts both ways: any reimbursement pushback, supply disruption, or delayed product cadence can re-rate the multiple quickly because the balance sheet offers limited error correction.

INSP is the higher-quality asset, but the market is already paying for that quality and then some. The real risk is not product demand, but policy timing: reimbursement/coding uncertainty can compress commercial conversion for multiple selling cycles, meaning the stock can be dead money for 2-3 quarters even if the long-term thesis remains intact. The cleaner capital structure and positive cash generation make it resilient, yet that also means the upside from “surprise-good” is likely more muted unless policy resolves decisively.

The competitive read is more interesting than the headline comparison. ATEC’s growth could force slower share gains from larger incumbents in spine to become more defense-oriented, potentially prompting price concessions or bundling behavior across Medtronic, JNJ, ZBH, and GMED. On the other side, INSP’s reimbursement uncertainty is a relative tailwind for RMD and other conventional therapy players in the near term, but if the policy overhang lifts, the market may have to reprice the entire sleep-apnea device category, not just INSP. That makes the setup asymmetric: ATEC is the nearer-term momentum trade, INSP is the policy-resolution call option.

Key Decisions for Investors

• Long ATEC vs. short basket of MDT/JNJ/ZBH/GMED on a 3-6 month horizon — best expression of share-gain momentum plus operating leverage; stop if ATEC growth decelerates for two consecutive quarters.
• Use INSP as a contrarian long only on policy dislocation, not on strength — prefer staged entry after reimbursement headlines create a 10-15% pullback; target 12-18 month horizon for re-rating.
• Avoid outright shorting INSP into binary policy windows — the stock has too much quality/ballast and can gap higher on any favorable Medicare clarity.
• For more aggressive risk, pair long ATEC / short RMD as a relative-value trade — if reimbursement uncertainty persists, RMD captures share defensively; if ATEC execution remains strong, its multiple can expand faster.
• If owning INSP, hedge with short-dated downside puts into CMS/DOJ-related dates; the catalyst path is event-driven, so premium is justified when implied vol is below policy-event realized vol.